# US 2024/0199702 A1 · Cell-permeable cyclic peptides and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199702 A1
- Document ID: US20240199702A1
- Status: Published application
- Kind: A1
- Application number: 18/516,155
- Filed: 2023-11-21
- Published: 2024-06-20
- Earliest claimed: 2021-05-26
- Assignees: Unnatural Products Inc.
- Applicants: Unnatural Products Inc.
- Inventors: Cameron PYE; Joshua SCHWOCHERT; Anthony SILVESTRI
- Web page: https://patentgrep.com/patent/US20240199702A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07K 7/64: Cyclic peptides containing only normal peptide links
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Cyclic peptides that inhibit MDM2 or MDM2 and MDM4, pharmaceutical compositions containing these cyclic peptides, and methods of using these cyclic peptides for inhibiting MDM2 or MDM2 and MDM4 are described herein.

## Claims

### Claim 1

A cyclic peptide comprising:
nine to eleven amino acid residues independently selected from amino acid residues that are not charged at physiological pH;
a first and a second beta hairpin region;
at least one amino acid residue with a side chain comprising a moiety selected from an ether, an ester, a carbonate, an amide, a carbamate, and a urea;
and characterized by one of the following:
at least four amino acid residues comprising rings independently selected from optionally substituted monocyclic carbocycle and optionally substituted monocyclic heterocycle, wherein at least one of the monocyclic carbocycle and monocyclic heterocycle are substituted;
at least four amino acid residues with side chains selected from -alkylene-(monocyclic carbocycle) and -alkylene-(monocyclic heterocycle), wherein the monocyclic carbocycle and monocyclic heterocycle are independently optionally substituted; and
at least three amino acid residues comprising rings independently selected from optionally substituted phenyl and optionally substituted monocyclic heteroaryl.

### Claim 2 (depends on 1)

The cyclic peptide of claim 1, wherein the first beta hairpin region comprises two contiguous amino acid residues.

### Claim 3 (depends on 2)

The cyclic peptide of claim 2, wherein the first beta hairpin region comprises two contiguous residues independently selected from: L-Pro, D-Pro, L-Aze, D-Pip, L-NMe-Phe, and D-NMe-Val, wherein the phenyl group of L-NMe-Phe is optionally substituted by one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —OH, —CN, —NO2, C1-4alkyl, —CH3, —CF3, —CHF2, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2.

### Claim 4 (depends on 3)

The cyclic peptide of claim 3, wherein the first beta hairpin region comprises two contiguous residues independently selected from: L-Pro, D-Pro, L-Aze, D-Pip, and D-NMe-Val.

### Claim 5 (depends on 4)

The cyclic peptide of claim 4, wherein for the two contiguous residues, one is D and the other is L.

### Claim 6 (depends on 5)

The cyclic peptide of claim 5, wherein the two contiguous amino acid residues are D-Pro and L-Pro.

### Claim 7 (depends on 5)

The cyclic peptide of claim 5, wherein the two contiguous amino acid residues are D-NMe-Val and L-Pro.

### Claim 8 (depends on 5)

The cyclic peptide of claim 5, wherein the two contiguous amino acid residues are D-Pro and L-NMe-Phe, wherein the phenyl group of L-NMe-Phe is optionally substituted by one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —OH, —CN, —NO2, C1-4alkyl, —CH3, —CF3, —CHF2, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The cyclic peptide of any one of claims 1 to 8, wherein the second beta hairpin region comprises a second two contiguous amino acid residues.

### Claim 10 (depends on 9)

The cyclic peptide of claim 9, wherein the second beta hairpin region comprises a second two contiguous residues independently selected from: D-Pro, a peptoid, a D-N-alkylated amino acid, and an L-N-alkylated amino acid.

### Claim 11 (depends on 10)

The cyclic peptide of claim 10, wherein the second beta hairpin region comprises a second two contiguous residues independently selected from: D-Pro, a peptoid, and an L-N-alkylated amino acid.

### Claim 12 (depends on 11)

The cyclic peptide of claim 11, wherein for the second two contiguous residues, one is a peptoid and the other is an L-N-alkylated amino acid.

### Claim 13 (depends on 12)

The cyclic peptide of claim 12, wherein for the second two contiguous residues, one is L-NMe-Ala and the other is N-(2-methoxyethyl)glycine.

### Claim 14 (depends on 10)

The cyclic peptide of claim 10, wherein for the second two contiguous residues, one is a D-N-alkylated amino acid and the other is an L-N-alkylated amino acid.

### Claim 15 (depends on 14)

The cyclic peptide of claim 14, wherein for the second two contiguous residues, one is D-NMe-Ala and the other is L-NMe-Ala.

### Claim 16 (depends on 11)

The cyclic peptide of claim 11, wherein for the second two contiguous residues, one is a D-N-alkylated amino acid and the other is a peptoid.

### Claim 17 (depends on 16)

The cyclic peptide of claim 16, wherein for the second two contiguous residues, one is D-NMe-Ala and the other is N-(2-methoxyethyl)glycine.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The cyclic peptide of any one of claims 1 to 17, wherein at least two contiguous amino acids separate the first beta hairpin region from the second beta hairpin region.

### Claim 19 (depends on 18)

The cyclic peptide of claim 18, wherein at least three contiguous amino acids separate the first beta hairpin region from the second beta hairpin region.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The cyclic peptide of any one of claims 1 to 19, wherein the molecular weight of the cyclic peptide is from 800 to 1300 Da.

### Claim 21 (depends on 20)

The cyclic peptide of claim 20, wherein the molecular weight of the cyclic peptide is from 800 to 1200 Da.

### Claim 22 (depends on 21)

The cyclic peptide of claim 21, wherein the molecular weight of the cyclic peptide is from 900 to 1200 Da.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The cyclic peptide of any one of claims 1 to 22, characterized by at least four amino acid residues comprising rings independently selected from optionally substituted monocyclic carbocycle and optionally substituted monocyclic heterocycle, wherein at least one of the monocyclic carbocycle and monocyclic heterocycle are substituted.

### Claim 24 (depends on 23)

The cyclic peptide of claim 23, wherein the optionally substituted monocyclic carbocycle is phenyl and optionally substituted monocyclic heterocycle is a heteroaryl ring, wherein at least one phenyl or heteroaryl ring is substituted by one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —OH, —CN, —NO2, C1-4alkyl, —CH3, —CF3, —CHF2, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2.

### Claim 25 (depends on 23, 24)

The cyclic peptide of claim 23 or 24, wherein the optionally substituted monocyclic carbocycle is phenyl and optionally substituted monocyclic heterocycle is a heteroaryl ring, wherein at least one phenyl or heteroaryl ring is substituted by one or more substituents independently selected from halo, —CH3, —CF3, —CHF2, —OBz, —OCH3, —OCF3, and —OCHF2.

### Claim 26 (depends on 23, 24, 25)

The cyclic peptide of any one of claims 23 to 25, wherein each heteroaryl ring is independently selected from thiophene, thiazole, oxazole, triazole, tetrazole, pyridine, pyrimidine, pyrazine, pyrrole, pyrazole, and imidazole, any one of which may be substituted.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The cyclic peptide of any one of claims 1 to 22, characterized by at least four amino acid residues with side chains selected from -alkylene-(monocyclic carbocycle) and -alkylene-(monocyclic heterocycle), wherein the monocyclic carbocycle and monocyclic heterocycle are independently optionally substituted.

### Claim 28 (depends on 27)

The cyclic peptide of claim 27, wherein each of the at least four amino acids with side chains selected from -alkylene-(optionally substituted monocyclic carbocycle) and -alkylene-(optionally substituted monocyclic heterocycle) are not adjacent to one another.

### Claim 29 (depends on 27, 28)

The cyclic peptide of claim 27 or 28, wherein two of the at least four amino acids with side chains selected from -alkylene-(optionally substituted monocyclic carbocycle) and -alkylene-(optionally substituted monocyclic heterocycle) are adjacent to one another.

### Claim 30 (depends on 27, 28, 29)

The cyclic peptide of any one of claims 27 to 29, wherein each monocyclic carbocycle is phenyl and each monocyclic heterocycle is a heteroaryl ring, wherein each phenyl and heteroaryl ring is independently optionally substituted by one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —OH, —CN, —NO2, C1-4alkyl, —CH3, —CF3, —CHF2, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2.

### Claim 31 (depends on 27, 28, 29, 30)

The cyclic peptide of any one of claims 27 to 30, wherein each monocyclic carbocycle is phenyl and each monocyclic heterocycle is a heteroaryl ring, wherein each phenyl and heteroaryl ring is independently optionally substituted by one or more substituents independently selected from halo, —CH3, —CF3, —CHF2, —OBz, —OCH3, —OCF3, and —OCHF2.

### Claim 32 (depends on 27, 28, 29, 30, 31)

The cyclic peptide of claim any one of claims 27 to 31, wherein each heteroaryl ring is independently selected from thiophene, thiazole, oxazole, triazole, tetrazole, pyridine, pyrimidine, pyrazine, pyrrole, pyrazole, and imidazole, any one of which is optionally substituted by one or more substituents independently selected from halo, —CH3, —CF3, —CHF2, —OBz, —OCH3, —OCF3, and —OCHF2.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The cyclic peptide of any one of claims 1 to 22, characterized by at least three amino acid residues comprising rings independently selected from optionally substituted phenyl and optionally substituted monocyclic heteroaryl.

### Claim 34 (depends on 33)

The cyclic peptide of claim 33, wherein each phenyl and heteroaryl ring is independently optionally substituted by one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —OH, —CN, —NO2, C1-4alkyl, —CH3, —CF3, —CHF2, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2.

### Claim 35 (depends on 33, 34)

The cyclic peptide of claim 33 or 34, wherein each phenyl and heteroaryl ring is independently optionally substituted by one or more substituents independently selected from halo, —CH3, —CF3, —CHF2, —OBz, —OCH3, —OCF3, and —OCHF2.

### Claim 36 (depends on 33, 34, 35)

The cyclic peptide of any one of claims 33 to 35, wherein each heteroaryl ring is independently selected from thiophene, thiazole, oxazole, triazole, tetrazole, pyridine, pyrimidine, pyrazine, pyrrole, pyrazole, and imidazole, any one of which is optionally substituted by one or more substituents independently selected from halo, —CH3, —CF3, —CHF2, —OBz, —OCH3, —OCF3, and —OCHF2.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The cyclic peptide of any one of claims 1 to 36, wherein at least three backbone nitrogen atoms of the cyclic peptide are tertiary nitrogens.

### Claim 38 (depends on 37)

The cyclic peptide of claim 37, wherein four or five backbone nitrogen atoms of the cyclic peptide are tertiary nitrogens.

### Claim 39 (depends on 38)

The cyclic peptide of claim 38, wherein four backbone nitrogen atoms of the cyclic peptide are tertiary nitrogens.

### Claim 40 (depends on 38)

The cyclic peptide of claim 38, wherein five backbone nitrogen atoms of the cyclic peptide are tertiary nitrogens.

### Claim 41 (depends on 37, 38, 39, 40)

The cyclic peptide of any one of claims 37 to 40, wherein one or more of the tertiary backbone nitrogen atoms are part of a heterocycloalkyl ring.

### Claim 42 (depends on 37, 38, 39, 40, 41)

The cyclic peptide of any one of claims 37 to 41, wherein one or more of the tertiary nitrogens have an optionally substituted C1-C6 alkyl substituent independently selected at each tertiary nitrogen and wherein substituents on C1-C6 alkyl are independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —OH, —CN, —NO2, C1-4 alkyl, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2.

### Claim 43 (depends on 37, 38, 39, 40, 41, 42)

The cyclic peptide of any one of claims 37 to 42, wherein one or more of the tertiary nitrogens have an optionally substituted C1-C6 alkyl substituent independently selected at each tertiary nitrogen and wherein substituents on C1-C6 alkyl are independently selected from halo, —OBz, —OCH3, —OCF3, and —OCHF2.

### Claim 44 (depends on 37, 38, 39, 40, 41, 42, 43)

The cyclic peptide of any one of claims 37 to 43, wherein each tertiary nitrogen is independently represented by:
wherein RA is C1-C6 alkyl optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —OH, —CN, —NO2, C1-4 alkyl, —OBz, —OCH3, —OCF3, and —OCHF2 and wherein
represents the point of connectivity to an adjacent amino acid residue.

### Claim 45 (depends on 37, 38, 39, 40, 41, 42, 43, 44)

The cyclic peptide of any one of claims 37 to 44, wherein each tertiary nitrogen is independently represented by:
wherein RA is C1-C6 alkyl optionally substituted with one or more substituents independently selected from halo, —OBz, —OCH3, —OCF3, and —OCHF2 and wherein
represents the point of connectivity to an adjacent amino acid residue.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The cyclic peptide of any one of claims 1 to 45, wherein the cyclic peptide has 10 amino acid residues.

### Claim 47

A cyclic peptide represented by Formula I:
wherein:
R1, R3, and R8 are independently selected from hydrogen, —(C1-4 alkylene)-(C3-8carbocycle), and —(C1-4 alkylene)-(3-10 membered heterocycle), wherein the C3-8carbocycle and 3-10 membered heterocycle are optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4alkyl, —OH, —CH3, —CF3, —CHF2, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2;
R2 is selected from hydrogen; and C1-6alkyl, C2-6alkenyl, and C2-6alkynyl, each of which is optionally substituted with one or more substituents independently selected from —OR21, —SR21, —N(R21)2, —C(O)R21, —C(O)N(R21)2, —N(R21)C(O)R21, —C(O)OR21, —OC(O)R21, —OC(O)N(R21)2, —N(R21)C(O)OR21, —OC(O)OR21, —N(R21)C(O)N(R21)2, —S(O)R21, —S(O)2R21, —P(O)(OR21)2, —OP(O)(OR21)2, ═O, ═S, ═N(R21), C3-10 carbocycle, and 3- to 10-membered heterocycle; wherein the carbocycle and heterocycle are independently optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4alkyl, —OH, —CH3, —CF3, —CHF2, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2; or R2 and R12 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl;
R4 is selected from hydrogen, C1-4 alkyl, —(C1-4alkylene)-(C3-8carbocycle), and —(C1-4alkylene)-(3-10 membered heterocycle), wherein the C3-8 carbocycle and 3-10 membered heterocycle are optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4alkyl, —OH, —CH3, —CF3, —CHF2, —OBz, —OCH3, —OCF3, —SF 5, and —OCHF2; and wherein the C1-4alkyl is optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4 alkyl, —OH, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2; or R4 and R14 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl;
R5 is hydrogen or C1-4 alkyl, or R5 and R15 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl;
R6 is selected from hydrogen, C1-4 alkyl, —(C1-4alkylene)-(C3-8carbocycle), and —(C1-4alkylene)-(3-10 membered heterocycle), wherein the C3-8 carbocycle and 3-10 membered heterocycle are optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4alkyl, —OH, —CH3, —CF3, —CHF2, —OBz, —OCH3, —OCF3, —SF 5, and —OCHF2; and wherein the C1-4alkyl is optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4 alkyl, —OH, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2;
R7 is selected from hydrogen; and C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-10 carbocycle, and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halo, C1-4alkyl, —OR21, —SR21, —N(R21)2, —C(O)R21, —C(O)N(R21)2, —N(R21)C(O)R21, —C(O)OR21, —OC(O)R21, —OC(O)N(R21)2, (R21)C(O)OR21, —OC(O)OR21, —N(R21)C(O)N(R21)2, —S(O)R21, S(O)2R21, —P(O)(OR21)2, —OP(O)(OR21)2, ═O, ═S, ═N(R21), C3-10 carbocycle, and 3- to 10-membered heterocycle; wherein the carbocycle and heterocycle are independently optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4alkyl, —OH, —CH3, —CF3, —CHF2, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2; or R7 and R17 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl; wherein at least one of R2 and R7 is not hydrogen or methyl;
R9 is hydrogen or C1-4 alkyl, or R9 and R19 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl;
R10 is selected from hydrogen; and C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-10 carbocycle, and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halo, C1-4alkyl, —OR21, —SR21, —N(R21)2, —C(O)R21, —C(O)N(R21)2, —N(R21)C(O)R21, —C(O)OR21, —OC(O)R21, —OC(O)N(R21)2, —N(R21)C(O)OR21, —OC(O)OR21, —N(R21)C(O)N(R21)2, —S(O)R21, —S(O)2R21, —P(O)(OR21)2, —OP(O)(OR21)2, ═O, ═S, ═N(R21), C3-10 carbocycle, and 3- to 10-membered heterocycle; wherein the carbocycle and heterocycle are independently optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4alkyl, —OH, —CH3, —CF3, —CHF2, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2; or It m and R20 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl;
R11, R13, R16 and R18 are independently selected from hydrogen; and C1-4alkyl optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4 alkyl, —OH, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2;
R12 is selected from hydrogen; and C1-4alkyl optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4 alkyl, —OH, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2, or R12 and R2 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl;
R14 is selected from hydrogen; and C1-4alkyl optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4 alkyl, —OH, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2, or R14 and R4 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl;
R15 is selected from hydrogen; and C1-4alkyl optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4 alkyl, —OH, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2, or R15 and R5 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl;
R17 is selected from hydrogen; and C1-4alkyl optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4 alkyl, —OH, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2, or R1 7 and R7 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl;
R19 is selected from hydrogen; and C1-4alkyl optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4 alkyl, —OH, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2 or R19 and R9 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl;
R20 is selected from hydrogen; and C1-4alkyl optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4 alkyl, —OH, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2, or R20 and R10 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl; and
R21 is independently selected at each occurrence from hydrogen; and C1-10 alkyl, C2-10alkenyl, C2-10 alkynyl, C3-8 carbocycle, and 3-10 membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, —OH, —CN, —NO2, —NH2, ═O, ═S, C2-10alkenyl, C2-10alkynyl, C1-10haloalkyl, C3-12 carbocycle, 3- to 12-membered heterocycle, —O(C1-10alkyl), —O(C2-10alkenyl), —O(C2-10alkynyl), —O(C3-8carbocycle), and —O(3-10 membered heterocycle).

### Claim 48 (depends on 47)

The cyclic peptide of claim 47, represented by Formula II:
wherein:
R21, R23, R26, and R28 are independently selected from hydrogen, —(C1-4 alkylene)-(C3-8carbocycle), and —(C1-4 alkylene)-(3-10 membered heterocycle), wherein the C3-8carbocycle and 3-10 membered heterocycle are optionally substituted with one or more substituents independently selected from halo, —OH, —CH3, —CF3, —CHF2, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2;
R22 is selected from hydrogen; and C1-6alkyl, C2-6alkenyl, and C2-6alkynyl, each of which is optionally substituted with one or more substituents independently selected from —OR21, —SR21, —N(R21)2, —C(O)R21, —C(O)N(R21)2, —N(R21)C(O)R21, —C(O)OR21, —OC(O)R21, —OC(O)N(R21)2, —N(R21)C(O)OR21, —OC(O)OR21, —N(R21)C(O)N(R21)2, —S(O)R21, —S(O)2R21, —P(O)(OR21)2, —OP(O)(OR21)2, ═O, ═S, ═N(R21), C3-10 carbocycle, and 3- to 10-membered heterocycle; wherein the carbocycle and heterocycle are independently optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4alkyl, —OH, —CH3, —CF3, —CHF2, —OBz, —OCH3, —OCF3, —SF 5, and —OCHF2; or R22 and R32 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl;
R24 is hydrogen or C1-4 alkyl, or R24 and R34 are taken together with the intervening atoms to form a 5- to 7-membered heterocycloalkyl;
R25 is hydrogen or C1-4 alkyl, or R25 and R35 are taken together with the intervening atoms to form a 5- to 7-membered heterocycloalkyl;
R27 is selected from hydrogen; and C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-10 carbocycle, and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halo, C1-4alkyl, —OR21, —SR21, —N(R21)2, —C(O)R21, —C(O)N(R21)2, —N(R21)C(O)R21, —C(O)OR21, —OC(O)R21, —OC(O)N(R21)2, —N(R21)C(O)OR21, —OC(O)OR21, —N(R21)C(O)N(R21)2, —S(O)R21, —S(O)2R21, —P(O)(OR21)2, —OP(O)(OR21)2, ═O, ═S, ═N(R21), C3-10 carbocycle, and 3- to 10-membered heterocycle; wherein the carbocycle and heterocycle are independently optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4alkyl, —OH, —CH3, —CF3, —CHF2, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2; or R27 and R37 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl; wherein at least one of R22 and R27 is not hydrogen or methyl;
R29 is hydrogen or C1-4 alkyl, or R29 and R39 are taken together with the intervening atoms to form a 5- to 7-membered heterocycloalkyl;
R30 is selected from hydrogen; and C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-10 carbocycle, and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halo, C1-4alkyl, —OR21, —SR21, —N(R21)2, —C(O)R21, —C(O)N(R21)2, —N(R21)C(O)R21, —C(O)OR21, —OC(O)R21, —OC(O)N(R21)2, —N(R21)C(O)OR21, —OC(O)OR21, —N(R21)C(O)N(R21)2, —S(O)R21, —S(O)2R21, —P(O)(OR21)2, —OP(O)(OR21)2, ═O, ═S, ═N(R21), C3-10 carbocycle, and 3- to 10-membered heterocycle; wherein the carbocycle and heterocycle are independently optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4alkyl, —OH, —CH3, —CF3, —CHF2, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2; or R30 and R40 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl;
R31, R33, R36, and R38 are independently selected from hydrogen; and C1-4alkyl optionally substituted with one or more substituents independently selected from halo, —OH, —OBz, —OCH3, —OCF3, —SF 5, and —OCHF2;
R32 is selected from hydrogen; and C1-4alkyl optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4 alkyl, —OH, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2, or R32 and R22 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl;
R34 is selected from hydrogen; and C1-4alkyl optionally substituted with one or more substituents independently selected from halo, —OH, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2, or R34 and R24 are taken together with the intervening atoms to form a 5- to 7-membered heterocycloalkyl;
R35 is selected from hydrogen; and C1-4alkyl optionally substituted with one or more substituents independently selected from halo, —OH, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2, or R35 and R25 are taken together with the intervening atoms to form a 5- to 7-membered heterocycloalkyl;
R37 is selected from hydrogen; and C1-4alkyl optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4 alkyl, —OH, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2, or R37 and R27 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl;
R39 is selected from hydrogen; and C1-4alkyl optionally substituted with one or more substituents independently selected from halo, —OH, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2 or R39 and R29 are taken together with the intervening atoms to form a 5- to 7-membered heterocycloalkyl;
R40 is selected from hydrogen; and C1-4alkyl optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4 alkyl, —OH, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2, or R40 and R30 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl; and
R41 is independently selected at each occurrence from hydrogen; and C1-10 alkyl, C2-10alkenyl, C2-10 alkynyl, C3-8carbocycle, and 3-10 membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, —OH, —CN, —NO2, —NH2, ═O, ═S, C1-10 alkyl, C2-10alkenyl, C2-10alkynyl, C1-10haloalkyl, C3-12 carbocycle, 3- to 12-membered heterocycle, —O(C1-10alkyl), —O(C2-10alkenyl), —O(C2-10alkynyl), —O(C3-8carbocycle), and —O(3-10 membered heterocycle).

### Claim 49 (depends on 48)

The cyclic peptide of claim 48, wherein R31, R33, R36, R37, and R38 are each hydrogen.

### Claim 50 (depends on 48, 49)

The cyclic peptide of claim 48 or 49, wherein at least four of R32, R34, R35, R39, and R40 are not hydrogen.

### Claim 51 (depends on 50)

The cyclic peptide of claim 50, wherein four of R32, R34, R35, R39, and R40 are not hydrogen.

### Claim 52 (depends on 50)

The cyclic peptide of claim 50, wherein R32, R34, R35, R39, and R40 are not hydrogen.

### Claim 53 (depends on 48, 49, 50, 51, 52)

The cyclic peptide of any one of claims 48 to 52, wherein at least one of R24 and R34, R25 and R35, and R29 and R39 are taken together with the intervening atoms to form a 5- to 7-membered heterocycloalkyl.

### Claim 54 (depends on 53)

The cyclic peptide of claim 53, wherein R24 and R34 are taken together with the intervening atoms to form a 5- to 6-membered heterocycloalkyl.

### Claim 55 (depends on 53)

The cyclic peptide of claim 53, wherein R25 and R35 are taken together with the intervening atoms to form a 5- to 6-membered heterocycloalkyl.

### Claim 56 (depends on 48, 49, 50, 51, 52, 53, 54, 55)

The cyclic peptide of any one of claims 48 to 55, wherein each of R32, R39, and R40 is selected from methyl and methoxyethyl.

### Claim 57 (depends on 48, 49, 50, 51, 52, 53, 55)

The cyclic peptide of any one of claim 48 to 53, 55, or 56, wherein each of R32, R34, R39, and R40 is selected from methyl and methoxyethyl.

### Claim 58 (depends on 48, 49, 50, 51, 52, 53, 54, 55)

The cyclic peptide of any one of claims 48 to 55, wherein R39 is C2-4alkyl optionally substituted with one or more substituents independently selected from halo, —OH, —OBz, —OCH3, —OCF3, and —OCHF2 or R29 and R39 are taken together with the intervening atoms to form a 5- to 7-membered heterocycloalkyl.

### Claim 59 (depends on 58)

The cyclic peptide of claim 58, wherein R39 is C2-4alkyl optionally substituted with one or more substituents independently selected from halo, —OH, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2.

### Claim 60 (depends on 48, 49, 50, 51, 52, 53, 54, 55)

The cyclic peptide of any one of claims 48 to 55, wherein R40 is C1-4alkyl optionally substituted with one or more substituents independently selected from halo, —OH, —OBz, —OCH3, —OCF3, and —OCHF2.

### Claim 61 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The cyclic peptide of any one of claims 48 to 60, wherein R22, R27, and R30 are independently selected from C1-6alkyl.

### Claim 62 (depends on 61)

The cyclic peptide of claim 61, wherein R22, R27, and R30 are selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, and t-butyl.

### Claim 63 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The cyclic peptide of any one of claims 48 to 60, wherein R22 and R27 are independently selected from C1-6 alkyl substituted with one or more substituents independently selected from —C(O)R41, —C(O)N(R41)2, —N(R41)C(O)R41, —C(O)OR41, —OC(O)R41, —OC(O)N(R41)2, —N(R41)C(O)OR41, —OC(O)OR41, and —N(R41)C(O)N(R41)2.

### Claim 64 (depends on 63)

The cyclic peptide of claim 63, wherein R22 is C1-6alkyl substituted with one or more substituents independently selected from —C(O)R41, —C(O)OR41, —OC(O)R41, and —OC(O)OR41.

### Claim 65 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

The cyclic peptide of any one of claims 48 to 64, wherein R21, R23, R26, and R28 are independently selected from —(C1-4 alkylene) —(C3-8carbocycle) and —(C1-4 alkylene)-(3-10 membered heterocycle), wherein the C3-8carbocycle and 3-10 membered heterocycle are optionally substituted.

### Claim 66 (depends on 65)

The cyclic peptide of claim 65, wherein R21, R23, R26, and R28 are independently selected from —CH2—(C3-8carbocycle), and —CH2-(3-10 membered heterocycle).

### Claim 67 (depends on 66)

The cyclic peptide of claim 66, wherein R21, R23, R26, and R28 are independently selected from phenylmethyl and pyridinylmethyl, wherein the phenyl and pyridinyl are optionally substituted.

### Claim 68 (depends on 67)

The cyclic peptide of claim 67, wherein R21, R23, R26, and R28 are independently selected from:

### Claim 69 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The cyclic peptide of any one of claims 48 to 68, wherein the compound is represented by Formula IIa:

### Claim 70 (depends on 69)

The cyclic peptide of claim 69, wherein the compound is represented by Formula IIb:
wherein R21′, R23′, R26′ and R28′ are independently selected from optionally substituted phenyl and optionally substituted 5-or 6-membered heteroaryl.

### Claim 71 (depends on 47)

The cyclic peptide of claim 47, represented by Formula III:
wherein:
R41, R43, R44 and R48 are independently selected from hydrogen, —(C1-4 alkylene)-(C3-8carbocycle), and —(C1-4 alkylene)-(3-10 membered heterocycle), wherein the C3-8carbocycle and 3-10 membered heterocycle are optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4 alkyl, —OH, —CH3, —CF3, —CHF2, —OBz, —OCH3, —OCF3, —SF 5, and —OCHF2;
R42 is selected from hydrogen; and C1-6alkyl, C2-6alkenyl, and C2-6alkynyl, each of which is optionally substituted with one or more substituents independently selected from —OR21, —SR21, —N(R21)2, —C(O)R21, —C(O)N(R21)2, —N(R21)C(O)R21, —C(O)OR21, —OC(O)R21, —OC(O)N(R21)2, —N(R21)C(O)OR21, —OC(O)OR21, —N(R21)C(O)N(R21)2, —S(O)R21, —S(O)2R21, —P(O)(OR21)2, —OP(O)(OR21)2, ═O, ═S, ═N(R21), C3-10 carbocycle, and 3- to 10-membered heterocycle; wherein the carbocycle and heterocycle are independently optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4alkyl, —OH, —CH3, —CF3, —CHF2, —OBz, —OCH3, —OCF3, —SF 5, and —OCHF2; or R42 and R52 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl;
R45 is hydrogen or C1-4 alkyl, or R45 and R55 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl;
R46 is selected from hydrogen; and C1-4alkyl optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4 alkyl, —OH, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2;
R47 is selected from hydrogen; and C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-10 carbocycle, and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halo, C1-4alkyl, —OR21, —SR21, —N(R21)2, —C(O)R21, —C(O)N(R21)2, —N(R21)C(O)R21, —C(O)OR21, —OC(O)R21, —OC(O)N(R21)2, —N(R21)C(O)OR21, —OC(O)OR21, —N(R21)C(O)N(R21)2, —S(O)R21, —S(O)2R21, —P(O)(OR21)2, —OP(O)(OR21)2, ═O, ═S, ═N(R21), C3-10 carbocycle, and 3- to 10-membered heterocycle; wherein the carbocycle and heterocycle are independently optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4alkyl, —OH, —CH3, —CF3, —CHF2, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2; or R47 and R57 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl; wherein at least one of R42 and R47 is not hydrogen or methyl;
R49 is hydrogen or C1-4 alkyl, or R49 and R59 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl;
R50 is selected from hydrogen; and C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-10 carbocycle, and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halo, C1-4alkyl, —OR21, —SR21, —N(R21)2, —C(O)R21, —C(O)N(R21)2, —N(R21)C(O)R21, —C(O)OR21, —OC(O)R21, —OC(O)N(R21)2, —N(R21)C(O)OR21, —OC(O)OR21, —N(R21)C(O)N(R21)2, —S(O)R21, —S(O)2R21, —P(O)(OR21)2, —OP(O)(OR21)2, ═O, ═S, ═N(R21), C3-10 carbocycle, and 3- to 10-membered heterocycle; wherein the carbocycle and heterocycle are independently optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4alkyl, —OH, —CH3, —CF3, —CHF2, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2; or R50 and R60 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl;
R51, R53, R56, and R58 are independently selected from hydrogen; and C1-4alkyl optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4 alkyl, —OH, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2;
R52 is selected from hydrogen; and C1-4alkyl optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4 alkyl, —OH, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2, or R52 and R42 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl;
R54 are independently selected from hydrogen; and C1-4 alkyl optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4 alkyl, —OH, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2;
R55 is selected from hydrogen; and C1-4alkyl optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4 alkyl, —OH, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2, or R55 and R45 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl;
R57 is selected from hydrogen; and C1-4alkyl optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4 alkyl, —OH, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2; or R57 and R47 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl;
R59 is selected from hydrogen; and C1-4alkyl optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4 alkyl, —OH, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2, or R59 and R49 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl;
R60 is selected from hydrogen; and C1-4alkyl optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4 alkyl, —OH, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2, or R60 and R50 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl; and
R61 is independently selected at each occurrence from hydrogen; and C1-10 alkyl, C2-10alkenyl, C2-10alkynyl, C3-8 carbocycle, and 3-10 membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, —OH, —CN, —NO2, —NH2, ═O, ═S, C1-10 alkyl, C2-10alkenyl, C2-10alkynyl, C1-10haloalkyl, C3-12 carbocycle, 3- to 12-membered heterocycle, —O(C1-10alkyl), —O(C2-10alkenyl), —O(C2-10alkynyl), —O(C3-8carbocycle), and —O(3-10 membered heterocycle).

### Claim 72 (depends on 71)

The cyclic peptide of claim 71, wherein R51, R53, R56, and R58 are each hydrogen.

### Claim 73 (depends on 71, 72)

The cyclic peptide of claim 71 or 72, wherein at least four of R52, R54, R55, R57, R59, and R60 are not hydrogen.

### Claim 74 (depends on 73)

The cyclic peptide of claim 73, wherein four of R52, R54, R55, R57, R59, and R60 are not hydrogen.

### Claim 75 (depends on 73)

The cyclic peptide of claim 73, wherein R52, R54, R55, R57, R59, and R60 are not hydrogen.

### Claim 76 (depends on 71, 72, 73, 74, 75)

The cyclic peptide of any one of claims 71 to 75, wherein at least one of R45 and R55, and R49 and R59 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl.

### Claim 77 (depends on 76)

The cyclic peptide of claim 76, wherein R45 and R55 are taken together with the intervening atoms to form a 4- to 6-membered heterocycloalkyl.

### Claim 78 (depends on 71, 72, 73, 74, 75, 76, 77)

The cyclic peptide of any one of claims 71 to 77, wherein each of R54, R59, and R60 is selected from methyl, ethyl, and methoxyethyl.

### Claim 79 (depends on 71, 72, 73, 74, 75, 76, 77, 78)

The cyclic peptide of any one of claims 71 to 78, wherein each of R54, R57, R59, and R60 is selected from methyl, ethyl, and methoxyethyl.

### Claim 80 (depends on 71, 72, 73, 74, 75, 76, 77)

The cyclic peptide of any one of claims 71 to 77, wherein R59 is C2-4alkyl optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4 alkyl, —OH, —OBz, —OCH3, —OCF3, —SF5, and —OCHF2, or R49 and R59 are taken together with the intervening atoms to form a 4- to 7-membered heterocycloalkyl.

### Claim 81 (depends on 80)

The cyclic peptide of claim 80, wherein R59 is C2-4alkyl optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4 alkyl, —OH, —OBz, —OCH3, —OCF3, and —OCHF2.

### Claim 82 (depends on 71, 72, 73, 74, 75, 76, 77)

The cyclic peptide of any one of claims 71 to 77, wherein R60 is C2-4alkyl optionally substituted with one or more substituents independently selected from halo, —SCH3, —SOCH3, —SO2CH3, —CN, —NO2, C1-4 alkyl, —OH, —OBz, —OCH3, —OCF3, and —OCHF2.

### Claim 83 (depends on 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

The cyclic peptide of any one of claims 71 to 82, wherein R42, R47, and R50 are independently selected from C1-6alkyl.

### Claim 84 (depends on 83)

The cyclic peptide of claim 83, wherein R42, R47, and R50 are selected from methyl, ethyl, propyl, i-propyl, butyl, i-butyl, and t-butyl.

### Claim 85 (depends on 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

The cyclic peptide of any one of claims 71 to 82, wherein R42 and R47 are independently selected from C1-6 alkyl substituted with one or more substituents independently selected from —C(O)R61, —C(O)N(R61)2, —N(R61)C(O)R61, —C(O)OR61, —OC(O)R61, —OC(O)N(R61)2, —N(R61)C(O)OR61, —OC(O)OR61, and —N(R61)C(O)N(R61)2.

### Claim 86 (depends on 85)

The cyclic peptide of claim 85, wherein R42 is C1-6alkyl substituted with one or more substituents independently selected from —C(O)R61, —C(O)OR61, —OC(O)R61, and —OC(O)OR61.

### Claim 87 (depends on 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86)

The cyclic peptide of any one of claims 71 to 86, wherein R41, R43, R44, and R48 are independently selected from —(C1-4 alkylene) —(C3-8carbocycle) and —(C1-4 alkylene)-(3-10 membered heterocycle), wherein the C3-8carbocycle and 3-10 membered heterocycle are optionally substituted.

### Claim 88 (depends on 87)

The cyclic peptide of claim 87, wherein R41, R43, R44, and R48 are independently selected from —CH2—(C3-8carbocycle), and —CH2-(3-10 membered heterocycle).

### Claim 89 (depends on 88)

The cyclic peptide of claim 88, wherein R41, R43, R44, and R48 are independently selected from phenylmethyl, pyridinylmethyl, and thiazolylmethyl, wherein the phenyl, pyridinyl, and thiazolyl are optionally substituted.

### Claim 90 (depends on 89)

The cyclic peptide of claim 89, wherein R41, R43, R44, and R48 are independently selected from:

### Claim 91 (depends on 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90)

The cyclic peptide of any one of claims 71 to 90, wherein the compound is represented by Formula IIIa:

### Claim 92 (depends on 91)

The cyclic peptide of claim 91, wherein the compound is represented by Formula IIIb:
wherein R41′, R43′, R44′, and R48′ are independently selected from optionally substituted phenyl and optionally substituted 5-or 6-membered heteroaryl.

### Claim 93 (depends on 1)

The cyclic peptide of claim 1, wherein the cyclic peptide is selected from those in Table 1, or a pharmaceutically acceptable salt of any one thereof.

### Claim 94 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93)

A pharmaceutical composition comprising a cyclic peptide of any one of claims 1 to 93 and a pharmaceutically acceptable excipient.

### Claim 95 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93)

A method of inhibiting MDM2, comprising administering a cyclic peptide of any one of claims 1 to 93 to a subject in need thereof.

### Claim 96 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93)

A method of inhibiting MDM2 and MDM4, comprising administering a cyclic peptide of any one of claims 1 to 93 to a subject in need thereof.

### Claim 97 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93)

A method of treating a disease or disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a cyclic peptide of any one of claims 1 to 93.

### Claim 98 (depends on 97)

The method of claim 97, wherein the disease or disorder is cancer.

### Claim 99 (depends on 98)

The method of claim 98, wherein the cancer is selected from acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia.

### Claim 100 (depends on 97)

The method of claim 97, wherein the disease or disorder is associated with the proliferation of senescent cells.

### Claim 101 (depends on 100)

The method of claim 100, wherein the disease or disorder associated with the proliferation of senescent cells is selected from a cardiovascular disease, an inflammatory disease, an auto-immune disease, a metabolic disease, a pulmonary disease, an ophthalmic disease, an otic disease, a renal disease, and a dermatological disease.

### Claim 102 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93)

A method of inducing the death of a senescent cell in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a cyclic peptide of any one of claims 1 to 93.
